Avapritinib
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
112 Active assets in the Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan AstraZeneca | Phase 3 | BBB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
FLUOROURACILUM Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
Eloxatin Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →